Skip to main content

Differential stability of cell-free circulating microRNAs: implications for their utilization as biomarkers.

Köberle V, Pleli T, Schmithals C, Augusto Alonso E, Haupenthal J, Bönig H, Peveling-Oberhag J, Biondi RM, Zeuzem S, Kronenberger B, Waidmann O, Piiper A

Publication: PLoS One (2013) • Vol 8 • Page e75184PMID: 24073250View on PubMed

Purpose

The purpose of this paper was to determine the effects of room temperature storage of serum, addition of RNase inhibitors, and blood cell lysis on micro-RNA (miRNA) levels in serum and in the vesicle and non-vesicle fractions of serum.

Conclusion

miRNA levels declined with room temperature incubation of serum, but the magnitude of the decline was dependent on the miRNA. The decrease in miRNA levels could be attenuated by the addition of RNAse inhibitor to serum or blood or by lysis of the blood. The ratio of miR-16, miR-122, miR-192 and miR-500 in the vesicle to the non-vesicle fraction of serum increased during storage indicating faster degradation of supernatant miRNAs than vesicle-associated miRNAs. miRNAs in the serum supernatant were more susceptible to RNAse A than those in the vesicles.

Studies (1)

Purpose

The purpose of this study was to determine the effects of room temperature storage of serum, addition of RNase inhibitors to blood or serum, and blood cell lysis on miRNA levels in serum and in the vesicle and non-vesicle fractions of serum. Serum from healthy individuals was centrifuged for 30 min at 10,000 g to remove cell fragments, mixed with PBS and then centrifuged at 120,000 g for 2 h at 4 degrees C to separate vesicles from non vesicle fractions. miRNAs were extracted using the miRNeasy Mini Kit. The number of specimens was not specified for all experiments, but for those in which it was specified, 3-5 specimens were used.

Summary of Findings

After 3 h at room temperature, levels of miR-1 and miR-122 were 40% of levels measured in fresh serum, but levels of miR-16, miR-21 and miR-142-3P remained at 75-80% of initial levels. After storage of serum for 24 h at room temperature, levels of miR-1 and miR-122 were 10% of the initial levels, levels of miR-16 and miR-21 were 40% of initial levels and levels of miR-142-3P were 60% of initial levels. The decreases in miR-16 and miR-122 levels were partially attenuated by the addition of 0.1 units/uL RNAse inhibitor to serum and almost completely prevented by the addition of 0.3 units/uL RNAse inhibitors to serum. Similarly, the levels of miR-122 were stabilized when RNAse inhibitors were added to blood prior to the isolation of serum. miR-122 levels were also stable in serum for 24 h at room temperature when blood was lysed with Triton-X but not when blood was left intact or RNAse A was added. The authors report that the addition of lysed red blood cells to serum also stabilized levels of miR-122. With increased incubation of serum, the ratio of miR-16, miR-122, miR-192 and miR-500 in the vesicle to the non-vesicle fraction of serum increased indicating faster degradation of supernatant miRNAs than vesicle-associated miRNAs. Further, levels of miR-16, miR-122 and miR-21 in the serum supernatant were more susceptible to RNAse A than those in the vesicles.

  • Biospecimens

    FluidSerum
    FluidBlood
  • Preservation Types

    None (Fresh)
  • Diagnoses

    Normal
  • Platforms

    RNAReal-time qRT-PCR
  • Pre-analytical Factors

    ClassificationPre-Analytical FactorValue(s)
    Biospecimen Aliquots and ComponentsBlood and blood products
    Serum
    Serum supernatant
    Serum vesicles
    Biospecimen Aliquots and ComponentsHemolysis
    Absent
    Chemically-induced
    Hemolysate added
    StorageTime at room temperature
    0 h
    1 h
    24 h
    3 h
    5 h
    Analyte Extraction and PurificationNucleic acid digestion
    No RNAse added
    RNAse A added
    Analyte Extraction and PurificationRNase inactivation
    0.1 units/uL RNAse inhibitor added
    0.3 units/uL RNAse inhibitor added
    0.5 units/uL RNAse inhibitor added
    No RNAse inhibitor added
    RNAse inhibitor added to blood
    RNAse inhibitor added to serum
    Real-time qRT-PCR SpecificTechnology platform
    miR-1
    miR-122
    miR-142-3p
    miR-16
    miR-192
    miR-21
    miR-500